"I thought Novo Nordisk was an example of “quality at a fair price” back in February at 29x earnings. I bought a starting position at that time. It is currently priced at 17x trailing earnings or 14x forward earnings. I now consider it to be undervalued."
Well, that is what many great investors like Sir John Templeton did, they would invest in pockets of extreme pessimism, while keeping a list of good stocks, but invest only in them when they were greatly undervalued. In my opinion, stocks like this are too volatile to settle with just fairly priced.
I think your analysis is spot on. Thank you for sharing. My main question now is why has NN been so slow to submit oral Semaglutide for FDA approval? Oasis 1 was 2023. Seems like they left the door open for Lilly to steal spotlight and free marketing when
"I thought Novo Nordisk was an example of “quality at a fair price” back in February at 29x earnings. I bought a starting position at that time. It is currently priced at 17x trailing earnings or 14x forward earnings. I now consider it to be undervalued."
Well, that is what many great investors like Sir John Templeton did, they would invest in pockets of extreme pessimism, while keeping a list of good stocks, but invest only in them when they were greatly undervalued. In my opinion, stocks like this are too volatile to settle with just fairly priced.
A fair opinion.
I like your style
I think your analysis is spot on. Thank you for sharing. My main question now is why has NN been so slow to submit oral Semaglutide for FDA approval? Oasis 1 was 2023. Seems like they left the door open for Lilly to steal spotlight and free marketing when
they had the lead.
Good read. I must admit it is attractive. Is there any difference in the safety profile of the NVO/LLY pipeline?
Very similiar side effects. Mostly nausea which resolved with time.
Great one